Prolonged effect of temporary rituximab therapy in neuromyelitis optica - A case study

被引:1
作者
Kotlega, Dariusz [1 ,2 ]
Golab-Janowska, Monika [1 ]
Nowacki, Przemyslaw [1 ]
机构
[1] Pomeranian Med Univ, Dept Neurol, Ul.Unii Lubelskiej 1, PL-71252 Szczecin, Poland
[2] Aldemed Centrum Medyczne, Zielona Gora, Poland
来源
POSTEPY PSYCHIATRII I NEUROLOGII | 2015年 / 24卷 / 04期
关键词
Neuromyelitis optica; Aquaporin; 4; Rituximab; Prolonged remission;
D O I
10.1016/j.pin.2015.11.002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim: Neuromyelitis optica is an autoimmune disorder connected with the effect of IgG antibodies against water channels (aquaporin-4) in the central nervous system. In the course of the disease, there is the involvement of the optic nerves and the spinal cord, resulting in a progressive disability. In the treatment, immunosuppressive agents are used as well as monoclonal antibodies such as rituximab (anti-CD20). According to the results, rituximab is the most effective, safe and recommended as a first-line treatment. Until now the duration and frequency of this therapy has not been established. The aim of this report is to provide the information necessary to create the optimal rituximab dosing regimen. Case: An NMO patient, who was treated with rituximab for 6 years depending on the blood CD19+ B lymphocytes titres, is presented here. The complete relapse restrain and clinical stabilisation were achieved, with beneficial effect remaining even after the rituximab treatment was terminated -present observation period is almost 4 years without any immunosuppressive or immunomodulating treatment. Since the treatment was stopped, the CD19+ B lymphocyte population tends to rise, but the neurological state has not changed. The most recent magnetic resonance imaging (MRI) of the cervical spine, from 2014, showed a post-inflammatory lesion between the medulla and the cervical spine, which had been present before, without any new inflammatory lesions. The IgG antibodies against AQP-4 assays were performed in 2013 for the first time and were negative. Comment: Temporary rituximab therapy in neuromyelitis optica may lead to a prolonged remission lasting some years. (C) 2015 Institute of Psychiatry and Neurology. Published by Elsevier Sp.zo. o.All rights reserved.
引用
收藏
页码:239 / 243
页数:5
相关论文
共 23 条
  • [1] Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study[J]. Asgari, Nasrin;Skejoe, Hanne Pernille Bro;Lillevang, Soeren Thue;Steenstrup, Troels;Stenager, Egon;Kyvik, Kirsten Ohm. BMC NEUROLOGY, 2013
  • [2] Patients with neuromyelitis optica have a more severe disease than patients with relapsing-remitting multiple sclerosis, including higher risk of dying of a demyelinating disease[J]. Bichuetti, Denis Bernardi;Lobato de Oliveira, Enedina Maria;de Souza, Nilton Amorin;Tintore, Mar;Gabbai, Alberto Alain. ARQUIVOS DE NEURO-PSIQUIATRIA, 2013(05)
  • [3] MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis[J]. Cassinotto, C.;Deramond, H.;Olindo, S.;Aveillan, M.;Smadja, D.;Cabre, P. JOURNAL OF NEURORADIOLOGY, 2009(04)
  • [4] An open label study of the effects of rituximab in neuromyelitis optica[J]. Cree, BAC;Lamb, S;Morgan, K;Chen, A;Waubant, E;Genain, C. NEUROLOGY, 2005(07)
  • [5] Evdoshenko E, 2013, ISRN NEUROL, V2013, DOI DOI 10.1155/2013/748127
  • [6] Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success[J]. Greenberg, Benjamin M.;Graves, Donna;Remington, Gina;Hardeman, Paula;Mann, Martha;Karandikar, Nitin;Stuve, Olaf;Monson, Nancy;Frohman, Elliot. MULTIPLE SCLEROSIS JOURNAL, 2012(07)
  • [7] Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience[J]. Jagtap, Sujit Abajirao;Mandliya, Alok;Sarada, C.;Nair, M. D. JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2015(03)
  • [8] Antibody to aquaporin-4 in the long-term course of neuromyelitis optica[J]. Jarius, S.;Aboul-Enein, F.;Waters, P.;Kuenz, B.;Hauser, A.;Berger, T.;Lang, W.;Reindl, M.;Vincent, A.;Kristoferitsch, W. BRAIN, 2008
  • [9] Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica[J]. Jiao, Yujuan;Fryer, James P.;Lennon, Vanda A.;Jenkins, Sarah M.;Quek, Amy M. L.;Smith, Carin Y.;McKeon, Andrew;Costanzi, Chiara;Iorio, Raffaele;Weinshenker, Brian G.;Wingerchuk, Dean M.;Shuster, Elizabeth A.;Lucchinetti, Claudia F.;Pittock, Sean J. NEUROLOGY, 2013(14)
  • [10] A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder[J]. Kim, Su-Hyun;Huh, So-Young;Lee, Sun Ju;Joung, Aeran;Kim, Ho Jin. JAMA NEUROLOGY, 2013(09)